Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Sudeep Pharma Ltd has opened its IPO for subscription, drawing strong attention from retail and NII investors today. The issue offers a mix of growth potential and sector stability, with early bidding trends providing a clear picture of investor sentiment. The IPO has already seen a 1.42x overall subscription, driven largely by non-institutional participation.
In this blog, we break down the day-wise subscription numbers, investor category trends, IPO details, and utilisation of proceeds. You can also review more insights in the Sudeep Pharma Ltd IPO page for deeper understanding.
Sudeep Pharma Ltd IPO recorded a 1.42x overall subscription today (as of Nov 21, 2025). Retail participation stood strong at 1.51x, while NII bids reached 3.00x, reflecting high demand from HNI investors. QIB (excluding anchor) participation remained muted at 0.09x, which is typical today as institutional investors often bid closer to closing day.
The momentum today suggests increasing traction across categories as the issue progresses.
Investor Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Rs Cr.)* |
Anchor Investors | 1 | 45,27,823 | 45,27,823 | 268.500 |
QIB (Ex Anchor) | 0.09 | 30,18,553 | 2,69,925 | 16.007 |
Non-Institutional Buyers | 3.00 | 22,63,912 | 67,93,800 | 402.872 |
bNII (bids above ₹10L) | 2.75 | 15,09,275 | 41,45,775 | 245.844 |
sNII (bids below ₹10L) | 3.51 | 7,54,637 | 26,48,025 | 157.028 |
Retail Investors | 1.51 | 52,82,462 | 79,51,350 | 471.515 |
Total ** | 1.42 | 1,05,64,927 | 1,50,15,075 | 890.394 |
Total Applications: 2,56,512 *Calculated at upper price band.
Sudeep Pharma Ltd IPO is a public offering of 1.51 crore equity shares, structured to attract diverse investor participation. Retail investors have been allocated 0.53 crore shares, while QIBs receive the largest portion at 0.75 crore shares, making up 50% of the issue size. NII investors hold a 15% allocation, divided into sNII and bNII categories for varied bidding preferences.
The IPO aims to support the company’s expansion plans and strengthen operational capabilities. With a total issue size of ₹895 crore, the offering positions Sudeep Pharma for its next phase of growth.
Shares Offered Breakdown
Category | Shares Offered | Amount (Rs Cr) | Size (%) |
Anchor Investor | 45,27,823 | 268.50 | 30.00% |
QIB | 75,46,376 | 447.50 | 50.00% |
NII | 22,63,912 | 134.25 | 15.00% |
bNII (bids above ₹10L) | 15,09,275 | 89.50 | 10.00% |
sNII (bids below ₹10L) | 7,54,637 | 44.75 | 5.00% |
Retail | 52,82,462 | 313.25 | 35.00% |
Total | 1,50,92,750 | 895.00 | 100% |
Funding expansion and capacity enhancement
Strengthening working capital requirements
Investment in R&D and process optimisation
General corporate purposes
Below is the anchor allocation structure as disclosed:
Particulars | Details |
Anchor Investor Bid Opening Date | Nov 20, 2025 |
Anchor Price | ₹593.00 per share |
Total Shares Allotted | 45,27,823 |
Allocation as % of QIB Portion | – |
Shares Locked for 30 Days | 0 |
Shares Locked for 90 Days | 0 |
Click here to check out recently closed IPO
The Sudeep Pharma Ltd IPO has begun on a positive note, especially with strong retail and NII participation shaping early demand. While QIB bids remain moderate today, institutional activity often accelerates closer to closing, making the upcoming days important to watch.
Overall, the IPO’s structure, anchor involvement, and subscription trends reflect healthy market interest. Investors can track day-wise updates to understand how the bidding pattern evolves across categories.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sudeep Pharma Ltd IPO.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading